Back

Cardiac troponins and anthracycline cardiotoxicity: a sub study of the PROACT trial; are all assays made equal?

21 June 2025 (10:05 - 10:50)
Organised by: Logo
Congress Presentation Part of: Decoding cardiac biomarkers and coronary interventions in patients with cancer Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Georgia Gilbert

The James Cook University Hospital, Middlesbrough (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Revascularization and mortality in ischemic heart disease among children, adolescents and young adults with cancer: Insights from the Rebuc Study
Doctor J. Sodling (Norrkoping, SE)
Abstract Slides
Presentation thumbnail
Features and predictors of 1-year outcomes in cancer patients discharged after acute coronary syndrome: insights from a multicenter registry.
Doctor L. Spadafora (Latina, IT)
Abstract Slides
Presentation thumbnail
Details of elevated troponin levels and clinical outcomes following immune checkpoint inhibitor treatment
Doctor Y. Shibutani (Kashiwa, JP)
Abstract Slides
Presentation thumbnail
Long-term outcomes of TAVI in patients with cancer: insights into early and late mortality trends
Doctor I. Nardi Agmon (Ramat Gan, IL)
Abstract Slides
Presentation thumbnail
Tracking cardiac troponin dynamics in patients treated with immune checkpoint inhibitors
Doctor E. Zatarain-Nicolas (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Decoding cardiac biomarkers and coronary interventions in patients with cancer

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources